Status:
COMPLETED
Effects of Buspirone in Opiate Withdrawal
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Heroin Dependence
Eligibility:
All Genders
25-55 years
Phase:
PHASE4
Brief Summary
Dependence on heroin is a major public health problem because of its association with criminality, law enforcement costs and healthcare costs. Managed withdrawal is a required first step for a long te...
Detailed Description
In an attempt to develop a new opiate detoxification approach, the authors assessed the efficacy of buspirone in the treatment of acute heroin withdrawal. Buspirone, a drug interacting with the seroto...
Eligibility Criteria
Inclusion
- fulfilled DSM IV diagnostic criteria for opioid dependence
- used heroin daily for at least the prior 6 months with claimed heroin use of at least 2.5g/week
- physical dependence on opiates as determined by history and observation
- admission urine samples demonstrating heroin use
- expressed willingness to participate in a randomized, double-blind, placebo-controlled study for 14 days.
Exclusion
- current or past Axis I psychiatric disorder other than opioid dependence
- evidence of significant neurological, gastrointestinal, hepatic, cardiovascular, renal, endocrine or hematologic disease
- seropositive status for the human immunodeficiency virus
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00326235
Start Date
January 1 2002
End Date
July 1 2004
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA New York Harbor Healthcare System - Brooklyn Campus
Brooklyn, New York, United States, 11209